Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics

por Marbury, Thomas C., Berg, Jolene Kay, Dove, Leonard S., Covington, Paul S.
Publicado 2017

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

por Dowell, James A., Marbury, Thomas C., Smith, William B., Henkel, Tim
Publicado 2022

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

por Marbury, Thomas C., Flint, Anne, Jacobsen, Jacob B., Derving Karsbøl, Julie, Lasseter, Kenneth
Publicado 2017

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients

por Maruyama, Sonomi, Marbury, Thomas C., Connaire, Jeffrey, Ries, Daniel, Maxwell, William, Rambaran, Curtis
Publicado 2020

Pharmacokinetic profile of defibrotide in patients with renal impairment

por Tocchetti, Paola, Tudone, Elena, Marier, Jean-Francois, Marbury, Thomas C, Zomorodi, Katie, Eller, Mark
Publicado 2016

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

por Hanley, Michael J., Kerstein, David, Tugnait, Meera, Narasimhan, Narayana, Marbury, Thomas C., Venkatakrishnan, Karthik, Gupta, Neeraj
Publicado 2023

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

por Ufer, Mike, Shakeri-Nejad, Kasra, Gardin, Anne, Su, Zhenzhong, Paule, Ines, Marbury, Thomas C., Legangneux, Eric
Publicado 2017

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

por Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Anderson, Jaclyn, Marbury, Thomas C., Othman, Ahmed A.
Publicado 2019

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment

por Hossain, Mohammad, Tiffany, Courtney, Tao, Yu, Barth, Aline, Marbury, Thomas C., Preston, Richard A., Dumont, Etienne
Publicado 2021

Effect of severe renal impairment on the pharmacokinetics of brigatinib

por Gupta, Neeraj, Hanley, Michael J., Kerstein, David, Tugnait, Meera, Narasimhan, Narayana, Marbury, Thomas C., Venkatakrishnan, Karthik
Publicado 2021

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

por Huguet, Jade, Ong, Voon, Sandison, Taylor, Melara, Rebeca M, Marbury, Thomas C, Jandourek, Alena, Flanagan, Shawn
Publicado 2021

705. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis

por Wicha, Wolfgang, Marbury, Thomas C, Dowell, James A, Lykens, Lori, Leister, Cathie, Ermer, James, Gelone, Steven P
Publicado 2019

722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function

por Wicha, Wolfgang, Marbury, Thomas C, Dowell, James A, Lykens, Lori, Leister, Cathie, Ermer, James, Gelone, Steven P
Publicado 2019

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study

por Chen, Xinhui, Cui, Xiaoming, Pognan, Nathalie, Quinlan, Michelle, Kapoor, Shruti, Rahmanzadeh, Gholamreza, Giovannini, Monica, Marbury, Thomas C.
Publicado 2021

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam

por Kletzl, Heidemarie, Ajmi, Hassan, Antys, Izabela, Heinig, Katja, Jaber, Birgit, Marbury, Thomas C., Young, Annie, Günther, Andreas
Publicado 2022

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment

por Geibel, Brooke, Dowell, James A, Marbury, Thomas C, Smith, William, McGovern, Paul C, Richards, Cynthia, Henkel, Tim
Publicado 2020

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension

por Smith, William B., Marbury, Thomas C., Komjathy, Steven F., Sumeray, Mark S., Williams, Gregory C., Hu, Ming-yi, Mould, Diane R.
Publicado 2012

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

por Hoover, Randall, Marbury, Thomas C., Preston, Richard A., Quintas, Megan, Lawrence, Laura E., Paulson, Susan K., Luke, David R., Cammarata, Sue K.
Publicado 2016

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studi...

por Kusawake, Tomohiro, Kowalski, Donna, Takada, Akitsugu, Kato, Kota, Katashima, Masataka, Keirns, James J., Lewand, Michaelene, Lasseter, Kenneth C., Marbury, Thomas C., Preston, Richard A.
Publicado 2017

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmac...

por Zahir, Hamim, Greenberg, Jonathan, Hsu, Ching, Marbury, Thomas C., Lasseter, Kenneth C., Xu, Li‐An, Tap, William D., Healey, John H., Stacchiotti, Silvia, LaCreta, Frank
Publicado 2022